Titan Pharmaceuticals, Inc

TheCryptoChartWhisperer

test $31.19 Gap Close Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992...

TheCryptoChartWhisperer

Test Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is...

PlanTradePlanMM

Downtrend Wedge breakout Price crossed SMA13,50 OBV>OBV34 WR buy signal near current price (my scripts: Williams %R two lines) Entry 2.6 Stop 2.0 Target 7.5 Risk management is much more important than a good entry point. The max Risk of each plan should be less than 1% of an account. I am not a PRO trader. I trade option to test my trading plan with small cost.

sfhenderson17

Starting my research, but like the upside potential on the chart...

NART11

Not an advice just a prediction will Targeting 3.90+ , and we will see

TheCryptoChartWhisperer

test $17.94 tp1 $50+ tp2

KozakHlib

Pupm&Dump trading strategy idea. $TTNP is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $4,15; stop-loss — $4.40; take-profit — $3.60; Do not view this idea as a recommendation for trading or investing. It is...

Alexey_Malorodov

NASDAQ:TTNP Hi, friends! It's been a long time, hasn't it? My investment fund management training is over. It's been very difficult, but it's over and I'm happy) There is still a lot of work ahead, of course. Nevertheless, I plan to get back to writing posts on this platform. For now, let's start with weekend posts so that many of you can read, analyze what I'...

HorizontalPriceLevelsTrading

Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. The company product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and...

mdstrobe

Analyzing chart with MA and other tools, I'm watching TTNP to head back to longer term moving averages.

TheCryptoChartWhisperer

test

simers.co

it's ready to start moving to 0.2 Rate and make a 50% Profit.

lemonsandshade

watch for breakout

Making_Profit

Right now the company have a bearish consolidation because is moving sideways under the SMA 200. I think it is in a 50/50 chance right now because the chart also have previous spikes reaching the resistance level. Will be better play support and resistance until the Stock Price take a direction. ***Remember*** This is only my Idea, don't buy or sell because of...

RCTcalibre

What can I say, I like wedges and I like cup and handles. I like this TTNP mini wedge, just don't see what catalyst will pump this up to be honest, but I like this chart. Remember I'm new at this, so I keep it simple.

mrfantano

We have a nice confirmation followed by a significant amount of consolidation... I'd rather call it accumulation to be honest. We have some money coming into the sector as a whole and it seems a good handful of these small Med-Tech companies are benefiting one by one, with these nice impulsive blasts. I think we have come to a point where we will some strong...

ssalman.uk

ttnp

Bullishcharts

Trade alert for break above Point of Control (redline) Earnings highlights Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. Q4 GAAP EPS of -$0.08 in-line. Revenue of $1.22M (-1.6% Y/Y) beats by $0.29M.